The Application of Emodin Treatment on Nasopharyngeal Carcinoma Therapy.
EBV
NPC therapy
emodin
nasopharyngeal carcinoma
natural compound
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
21 Feb 2024
21 Feb 2024
Historique:
received:
30
12
2023
revised:
02
02
2024
accepted:
08
02
2024
medline:
28
3
2024
pubmed:
28
3
2024
entrez:
28
3
2024
Statut:
epublish
Résumé
Nasopharyngeal carcinoma (NPC) is a malignancy prevailing in Taiwan, Hong Kong, Southern China, Southeast Asia, and North Africa. Although early-stage NPC responds well to the primary treatment of radio-chemotherapy, the mortality rate of advanced NPC remains high. Therefore, developing new therapies for nasopharyngeal carcinoma is an urgent task. Emodin is an anthraquinone derivative mainly found in
Identifiants
pubmed: 38540100
pii: biomedicines12030486
doi: 10.3390/biomedicines12030486
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : China Medical University Hospital, Taiwan
ID : EXO-113-016
Organisme : National Science and technology council, Taiwan
ID : MOST 110-2320-B-039-009